William Blair Has Pessimistic View of Medpace Q2 Earnings

Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) - Stock analysts at William Blair dropped their Q2 2025 earnings per share estimates for shares of Medpace in a research report issued to clients and investors on Tuesday, April 22nd. William Blair analyst M. Smock now forecasts that the company will post earnings per share of $3.02 for the quarter, down from their previous estimate of $3.09. William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for Medpace's current full-year earnings is $12.29 per share. William Blair also issued estimates for Medpace's FY2025 earnings at $12.45 EPS, Q3 2026 earnings at $3.11 EPS, Q4 2026 earnings at $3.05 EPS and FY2026 earnings at $12.45 EPS.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.06 by $0.61. The business had revenue of $558.57 million during the quarter, compared to analysts' expectations of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same quarter last year, the business posted $3.20 EPS.

Several other research firms have also recently weighed in on MEDP. Truist Financial decreased their target price on Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a research note on Wednesday, April 23rd. TD Cowen cut Medpace from a "buy" rating to a "hold" rating and decreased their target price for the stock from $370.00 to $328.00 in a research note on Monday, April 14th. Robert W. Baird decreased their target price on Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Mizuho decreased their target price on Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. Finally, Leerink Partners initiated coverage on Medpace in a research note on Monday, March 24th. They set a "market perform" rating and a $330.00 target price for the company. Eleven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $349.30.

Medpace Stock Performance

Shares of MEDP traded down $0.37 during midday trading on Friday, hitting $298.18. The company had a trading volume of 390,361 shares, compared to its average volume of 340,141. The company's 50-day simple moving average is $313.79 and its 200-day simple moving average is $331.60. The firm has a market capitalization of $8.57 billion, a P/E ratio of 23.61, a P/E/G ratio of 3.81 and a beta of 1.46. Medpace has a 1 year low of $250.05 and a 1 year high of $459.77.

Insider Activity

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the sale, the director now owns 2,998 shares in the company, valued at $904,856.36. This trade represents a 36.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 20.30% of the company's stock.

Institutional Trading of Medpace

Several hedge funds and other institutional investors have recently made changes to their positions in MEDP. Lindbrook Capital LLC raised its position in Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after acquiring an additional 29 shares during the last quarter. HBK Sorce Advisory LLC raised its position in Medpace by 0.5% during the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock worth $1,789,000 after acquiring an additional 29 shares during the last quarter. Assetmark Inc. raised its position in Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after acquiring an additional 29 shares during the last quarter. Proficio Capital Partners LLC raised its position in Medpace by 4.1% during the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock worth $243,000 after acquiring an additional 29 shares during the last quarter. Finally, Schulhoff & Co. Inc. raised its position in Medpace by 1.2% during the fourth quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock worth $874,000 after acquiring an additional 30 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.